Jason Amello is CFO & VP +1 at Akebia Therapeutics, Inc. (AKBA). They have made 6 open-market trades across 3 companies since 2010, most recently 2023-11-28.
CIK 0001451805
3 open-market purchases totalling $91K since 2014, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CADL | BUY | 2022-12-08 | 2022-12-12 | $1.80 | $10K | -34.7% | -27.5% | -40.8% |
| AKBA | SELL | 2020-02-28 | 2020-03-02 | $8.70 | $121K | -33.2% | -26.6% | +22.9% |
| AKBA | BUY | 2014-11-26 | 2014-12-01 | $13.22 | $13K | -38.5% | -0.9% | -0.9% |
| AKBA | BUY | 2014-03-25 | 2014-03-27 | $17.00 | $68K | -38.5% | -0.9% | -0.9% |
| GENZ | SELL | 2010-08-31 | 2010-09-02 | $70.30 | $467K | N/A | N/A | N/A |
| GENZ | SELL | 2010-05-25 | 2010-05-26 | $45.62 | $24K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.